Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts
Jeremy Petrous, Kevin M. Furmaga
BMJ Case Reports (2017), pp. bcr-222037
Open Access | Times Cited: 23

Showing 23 citing articles:

Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders
Ying Han, Kai Yuan, Yongbo Zheng, et al.
Neuroscience Bulletin (2019) Vol. 36, Iss. 4, pp. 432-448
Open Access | Times Cited: 77
Orexin/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: Potential for therapy
Cliff H. Summers, Jazmine D. W. Yaeger, Clarissa D. Staton, et al.
Brain Research (2018) Vol. 1731, pp. 146085-146085
Open Access | Times Cited: 59
Prescription Drugs Used in Insomnia
Sylvie Dujardin, Angelique Pijpers, Dirk Pevernagie
Sleep Medicine Clinics (2020) Vol. 15, Iss. 2, pp. 133-145
Closed Access | Times Cited: 39
Sleep-related drugs utilization and suicide behaviors: a population-based study in China
Yunshu Zhang, Bo Liu, Keqing Li, et al.
BMC Public Health (2025) Vol. 25, Iss. 1
Open Access
The Insomnia-Addiction Positive Feedback Loop: Role of the Orexin System
Jennifer E. Fragale, Morgan H. James, Jorge A. Avila, et al.
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 117-127
Open Access | Times Cited: 29
Prescription Drugs Used in Insomnia
Sylvie Dujardin, Angelique Pijpers, Dirk Pevernagie
Sleep Medicine Clinics (2018) Vol. 13, Iss. 2, pp. 169-182
Closed Access | Times Cited: 35
Role of orexin in pathogenesis of neurodegenerative parkinsonisms
Piotr Alster, Natalia Madetko, Dagmara Otto‐Ślusarczyk, et al.
Neurologia i Neurochirurgia Polska (2023) Vol. 57, Iss. 4, pp. 335-343
Open Access | Times Cited: 9
Drug-induced depressive symptoms: An update through the WHO pharmacovigilance database
Julien Li, Yoann Zelmat, Wilhelm Storck, et al.
Journal of Affective Disorders (2024) Vol. 350, pp. 452-467
Closed Access | Times Cited: 3
Safety of Dual Orexin Receptor Antagonist Daridorexant: A Disproportionality Analysis of Publicly Available FAERS Data
Giuseppe Cicala, María Antonietta Barbieri, Giulia Russo, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 342-342
Open Access | Times Cited: 3
Depression and anxiety of medical students at Kunming Medical University during COVID-19: A cross-sectional survey
Ying Guo, Shunda Li, Lanchun Zhang, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 14
Introduction to the Special Issue: “Making orexin-based therapies for addiction a reality: What are the steps from here?”
Morgan H. James, Gary Aston‐Jones
Brain Research (2020) Vol. 1731, pp. 146665-146665
Open Access | Times Cited: 22
Counterbalanced microcircuits for Orx1 and Orx2 regulation of stress reactivity
Jazmine D. W. Yaeger, Kevin T. Krupp, Jason J. Gale, et al.
Medicine in Drug Discovery (2020) Vol. 8, pp. 100059-100059
Open Access | Times Cited: 14
Hypocretin (Orexin) Replacement Therapies
Erica Seigneur, Luı́s de Lecea
Medicine in Drug Discovery (2020) Vol. 8, pp. 100070-100070
Open Access | Times Cited: 12
Safety of Dual Orexin Receptor Antagonist Daridorexant: A Dispropor-tionality Analysis of Publicly Available FAERS Data
Giuseppe Cicala, María Antonietta Barbieri, Giulia Russo, et al.
(2024)
Open Access | Times Cited: 1
Data mining and safety analysis of dual orexin receptor antagonists (DORAs): a real-world pharmacovigilance study based on the FAERS database
Manxue Jiang, Hao Li, Lingti Kong
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Hypocretin modulation of behavioral coping strategies for social stress
Pei Luo, Brian C. Trainor
Neuroscience (2024) Vol. 564, pp. 126-134
Closed Access | Times Cited: 1
Prescription Drugs Used in Insomnia
Sylvie Dujardin, Angelique Pijpers, Dirk Pevernagie
Sleep Medicine Clinics (2022) Vol. 17, Iss. 3, pp. 315-328
Closed Access | Times Cited: 7
Lemborexant, an orexin receptor antagonist sedative-hypnotic: Is it useful for insomnia in psychiatric disorders?
Nicholas A Keks, Judy Hope
Australasian Psychiatry (2022) Vol. 30, Iss. 4, pp. 530-532
Closed Access | Times Cited: 4
Drug-induced psychiatric disorders: A pharmacovigilance update
François Montastruc, Tanguy Taillefer de Laportalière
Therapies (2023) Vol. 79, Iss. 2, pp. 173-179
Closed Access | Times Cited: 2
Orexin Receptor Antagonists as an Adjunct for the Treatment of Depression: A mini meta-analysis
Mustafa Uğurlu
Nöro Psikiyatri Arşivi (2023)
Closed Access | Times Cited: 1
Suvorexant in the Treatment of Difficulty Falling and Staying Asleep (Insomnia).
Amnon A. Berger, Emily Sottosanti, Ariel Winnick, et al.
PubMed (2022) Vol. 52, Iss. 1, pp. 68-90
Closed Access | Times Cited: 2
Suvorexant

Reactions Weekly (2017) Vol. 1679, Iss. 1, pp. 193-193
Closed Access
Page 1

Scroll to top